Avoro Capital Advisors LLC Has $390.01 Million Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Avoro Capital Advisors LLC increased its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 10.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,222,222 shares of the company’s stock after buying an additional 1,111,111 shares during the period. Apellis Pharmaceuticals comprises approximately 5.5% of Avoro Capital Advisors LLC’s holdings, making the stock its 6th largest holding. Avoro Capital Advisors LLC owned about 0.10% of Apellis Pharmaceuticals worth $390,011,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. National Bank of Canada FI raised its holdings in shares of Apellis Pharmaceuticals by 266,361.5% in the 4th quarter. National Bank of Canada FI now owns 1,385,600 shares of the company’s stock valued at $44,214,000 after purchasing an additional 1,385,080 shares in the last quarter. Cibc World Markets Corp bought a new stake in Apellis Pharmaceuticals during the fourth quarter valued at about $41,014,000. Norges Bank purchased a new position in Apellis Pharmaceuticals in the fourth quarter valued at about $34,662,000. Jennison Associates LLC raised its holdings in Apellis Pharmaceuticals by 51.6% in the fourth quarter. Jennison Associates LLC now owns 2,760,404 shares of the company’s stock worth $88,084,000 after purchasing an additional 939,289 shares in the last quarter. Finally, Natixis purchased a new stake in shares of Apellis Pharmaceuticals during the fourth quarter valued at about $27,782,000. 96.29% of the stock is currently owned by institutional investors.

Insider Transactions at Apellis Pharmaceuticals

In related news, General Counsel David O. Watson sold 5,569 shares of Apellis Pharmaceuticals stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total value of $139,781.90. Following the completion of the transaction, the general counsel now owns 138,730 shares in the company, valued at $3,482,123. The trade was a 3.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO James George Chopas sold 1,096 shares of the stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total value of $33,351.28. Following the transaction, the chief accounting officer now owns 48,138 shares in the company, valued at $1,464,839.34. This represents a 2.23 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 36,011 shares of company stock valued at $1,059,969 in the last 90 days. 6.80% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms recently commented on APLS. HC Wainwright reiterated a “buy” rating and set a $57.00 price objective on shares of Apellis Pharmaceuticals in a research note on Monday, March 3rd. JPMorgan Chase & Co. increased their price target on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an “overweight” rating in a research note on Tuesday, March 4th. Scotiabank boosted their price target on Apellis Pharmaceuticals from $30.00 to $31.00 and gave the stock a “sector perform” rating in a research note on Wednesday, April 2nd. Wedbush decreased their price objective on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd. Finally, The Goldman Sachs Group lowered their target price on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research note on Monday, March 3rd. Eight research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $45.59.

Apellis Pharmaceuticals Trading Up 0.2 %

NASDAQ APLS opened at $18.20 on Monday. The company has a fifty day moving average of $23.72 and a 200 day moving average of $28.00. The company has a market capitalization of $2.28 billion, a PE ratio of -8.97 and a beta of 0.85. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals, Inc. has a 1 year low of $17.49 and a 1 year high of $50.98.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Friday, February 28th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.08. The firm had revenue of $212.50 million for the quarter, compared to the consensus estimate of $197.92 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company’s revenue was up 45.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.73) earnings per share. Research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).